Professor Ioannis S. Patrikios completed his PhD studies in 1994 from the Graduate School and University Center City University of New York, USA, specialized on Immunology and Lipids/Lipidomics and he continued post-doctoral studies specialization in Medical Biochemistry. Professor Patrikios went through several different fellowships/collaborations with high reputation institutions in USA and he was awarded advanced Immunology specialization courses at Scuola Superiore d'Immunologia Ruggero Ceppellini, Italy. He served and continues to serve as Executive Research Scientific Consultant for Industry and higher education. In the year 2000 he repatriated to Cyprus and was hosted by the Cyprus Institute of Neurology and Genetics. As from 2003, Professor Patrikios got involved in the research of innovative, pioneer, holistic therapeutic approaches for chronic multifactorial Neurodegenerative diseases, specifically of Multiple Sclerosis. His broad research interests include studies of new therapeutic approaches of chronic diseases by the use of Systems Medicine, through Systems Biology and Nutritional Systems Biology; Lipid Hemagglutinins and the use of natural extracts for cancer treatment. His 2002 research findings on the effect of frying oils as human hemagglutinins got an international interest. He served as a member of the group representing the National Committee of Cyprus at the European Advisory Council for Quality (ISO) for more than five consecutive years. He has been appointed as a reviewer of international scientific journals in the field of Medicine, Biochemistry, Pharmaceuticals-Therapeutics and Neurology and as a reviewer for national as well as international research grants. Professor Patrikios is a member of several International associations and bodies including Sigma Xi. He is the chief scientific investigator of the team that lately invented, developed and patented the nutraceutical formula PLP10 as a new therapeutic intervention for multiple sclerosis. He is the co-founder and Director of PALUPA Medical Ltd (a research and innovation company), that performed and successfully completed the phase II clinical trial for PLP10. Now he is the scientific coordinator of the “MINERAL” phase III multicenter clinical trial study for neuroaspis® PLP10. He is the founder and general organizer of the annual International Multithematic Biomedical Scientific Cyprus (BSC) congress (in November) that is taking place at the School of Medicine of the European University of Cyprus (EUC). At present he is a Professor and faculty member of the School of Medicine of EUC where he served as chairman and acting Deputy Dean during the first two years of the newly formed Medical School and continued to be affiliated as a research collaborator at the Cyprus Institute of Neurology and Genetics.
New therapeutic approaches of chronic diseases especially multiple sclerosis